Medx Health Corp.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John Gevisser
- Full Time Employees
- 312
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1495 Bonhill Road Mississauga ON Canada L5T 1M2
- IPO Date
- Jan 10, 2008
- Website
- medxhealth.com
- Similar Companies
- Business
- MedX Health Corp. develops, manufactures and commercializes medical-device and software solutions for skin health, dermatology, teledermatology, clinical research and photobiomodulation therapy. Incorporated in 1999 and headquartered in Mississauga, Ontario, Canada, the Company serves healthcare providers, dermatologists, health systems, payers, contract research organizations, academic institutions and enterprise partners in Canada, the United States, Europe and other international markets. Its principal offerings include DermSecure®, an FDA-cleared software-as-a-medical-device teledermatology platform that combines secure patient-record management, clinical imaging, subsurface lesion analysis, remote dermatologist review and care-triage workflows for the early assessment and detection of suspicious moles, lesions and other skin conditions; SIAscopy® and SIAScope® imaging technology, including SIAMETRICS®, SIMSYS® and MoleMate® devices, which use patented light-based imaging to non-invasively measure and visualize skin characteristics and biomarkers, including melanin, hemoglobin, collagen, pigmentation and vascularity, up to approximately two millimeters below the skin surface; SkinSecure™, a cloud-based software-as-a-service platform that uploads and analyzes chromophore images for clinical-trial and skin-health research workflows, enabling quantitative, longitudinal assessment of subdermal changes in melanin, hemoglobin and collagen; and Class IIIb photobiomodulation laser systems for non-invasive, drug-free pain management, inflammation reduction, tissue repair and cellular healing. Its laser-therapy portfolio includes rehabilitation console, portable and home-use systems, as well as OraLase® dental lasers and LumaVet veterinary cold-laser systems for oral-care, animal-health, pain-management and tissue-healing applications. MedX’s products and platform are designed for regulated healthcare environments and are supported by FDA clearance, Health Canada approvals, CE accreditation, ISO 13485 quality-management standards and MDSAP-aligned processes; its data infrastructure is designed to support HIPAA and GDPR compliance and interoperability with healthcare, claims, research and clinical-trial systems through HL7 FHIR standards. The Company reports deployments across 37 territories and operates through direct and partner-led distribution and service arrangements. Recent strategic developments include the June 2026 launch of SkinSecure as a cloud-based SaaS offering linking SIAScope imaging devices with clinical-research organization workflows and providing objective biological measurement for skin-health research; the 2025 introduction of the LumaVet veterinary laser line and OraLase dental laser SKU; the May 2025 partnership with Vitamed Biomedical and Medispa to expand teledermatology services in Italy; and management and product-development enhancements, including the appointment of John Gevisser as chief executive officer in May 2025 and the addition of strategic advisers focused on skin science, artificial intelligence and product development.
Company News
MedX Health Appoints Monaderm as a Representative for SkinSecure™ Across Europe for Beauty and Aesthetics Research
MedX Announces Final Closing of Non-brokered Private Placement
MedX Announces Application for Final Extension of Non-Brokered Private Placement
MedX Announces Application for Extension of Non-Brokered Private Placement
MedX Announces $2,700,000 Initial Closing of Non-Brokered Private Placement of Series IV Convertible Loan Notes
MedX Announces Non-Brokered Private Placement of Series IV Convertible Loan Notes
MedX Health 2025 YEAR REVIEW
MedX Announces Final Closing of Non-Brokered Private Placement
MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement
MedX Health Appoints Dr. Symon Cotton as Strategic Advisor on AI & Product Development
MedX Health Appoints Global Skin Science Leader Dr. Paul Matts as Strategic Advisor
MedX Announces Proposed Extension of Non-Brokered Private Placement
MedX Health Corp. Names Meghan Geary as Senior Vice President of Operations
MedX Announces Proposed Non-Brokered Private Placement to Raise up to $2,500,000 and Stock Option Grants
MedX Health Corp. Names John Gevisser as Chief Executive Officer
MedX Announces the Engagement of Market Maker Consultant
MedX Announces Final Closing of Non-Brokered Private Placement
MedX Health, Vitamed Biomedical, and Medispa Partner to Expand Teledermatology Services Across Italy
MDXH Stock: 38.06% Fall Explained
MedX Health says its SIAscopy/DermSecure products show significant promise as it reports Q1 results